Study of Liposomal Irinotecan in Advanced Colorectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new form of chemotherapy called liposomal irinotecan (Nal-IRI) for people with advanced colorectal cancer or other solid tumors. The goal is to see how well it works and how safe it is in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to other parts of the body (metastatic) and cannot be removed with surgery.
- You have already had at least one type of chemotherapy for your metastatic cancer, and it stopped working.
- You have not had irinotecan or liposomal irinotecan before (for most groups).
- You have not been treated with certain immune checkpoint inhibitors (like pembrolizumab or nivolumab) planned during this trial.
- You are not pregnant, not breastfeeding, and not allergic to irinotecan or liposomal irinotecan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of chemotherapy (liposomal irinotecan) combined with two standard drugs (5-FU and leucovorin) and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and helps people live longer.
This trial tests a new version of the chemotherapy drug irinotecan (called liposomal irinotecan) combined with bevacizumab, a targeted therapy, for people with colorectal cancer that has spread and has stopped responding to irinotecan. The goal is to see if this combination can control the tumor better.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) for people with advanced, aggressive neuroendocrine cancer that has not responded to at least one prior treatment. The goal is to see if this version of the drug works better or has fewer side effects.
This trial tests adding irinotecan liposomes to standard treatment for locally advanced rectal cancer before surgery. The goal is to see if this combination works better at shrinking the tumor and preventing it from coming back.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.